Abstract The membrane voltage clock and calcium (Ca 2? ) clock jointly regulate sinoatrial node (SAN) automaticity. VK-II-36 is a novel carvedilol analog that suppresses sarcoplasmic reticulum (SR) Ca 2? release but does not block the b-receptor. The effect of VK-II-36 on SAN function remains unclear. The purpose of this study was to evaluate whether VK-II-36 can influence SAN automaticity by inhibiting the Ca 2? clock. We simultaneously mapped intracellular Ca 2? and membrane potential in 24 isolated canine right atriums using previously described criteria of the timing of late diastolic intracellular Ca elevation (LDCAE) relative to the action potential upstroke to detect the Ca 2? clock. Pharmacological interventions with isoproterenol (ISO), ryanodine, caffeine, and VK-II-36 were performed after baseline recordings. VK-II-36 caused sinus rate downregulation and reduced LDCAE in the pacemaking site under basal conditions (P \ 0.01). ISO induced an upward shift of the pacemaking site in SAN and augmented LDCAE in the pacemaking site. ISO also significantly and dose-dependently increased the sinus rate. The treatment of VK-II-36 (30 lmol/l) abolished both the ISO-induced shift of the pacemaking site and augmentation of LDCAE (P \ 0.01), and it suppressed the ISO-induced increase in sinus rate (P = 0.02). Our results suggest that the sinus rate may be partly controlled by the Ca 2? clock via SR Ca 2? release during b-adrenergic stimulation.
Introduction
The mechanism of spontaneous diastolic depolarization (DD) of sinoatrial node (SAN) cells has traditionally been attributed to a membrane voltage clock mechanism, mediated by voltage-sensitive membrane currents, such as the hyperpolarization-activated pacemaker current (I f ) regulated by cAMP [1, 2] . It was reported that ivabradine, a selective I f current inhibitor, reduces the spontaneous heart rate and has cardioprotective effects [3] . Some more recent studies implicate a complementary ''Ca 2? clock'' mechanism mediated by Ca 2? release from the sarcoplasmic reticulum (SR) causing DD via activation of the Na/Ca exchanger current (I NCX ), which coordinately regulates sinus rate along with the membrane clock [4] [5] [6] . Recently, Himeno et al. [7] provided mathematical modeling and guinea pig single-cell data supporting the predominance of the membrane clock in regulating SAN automaticity. Therefore, it remains unclear whether or not the Ca 2? clock plays an important role in controlling the sinus rate.
Ca 2? can be released from the SR through activation of the ryanodine receptor (RyR). Under normal conditions, the L-type Ca 2? channels are activated, leading to a small Ca 2? influx. This Ca 2? influx then activates RyRs, resulting in a large Ca 2? release from the SR and subsequent muscle contraction. The process is known as calciuminduced calcium release (CICR) [8] . In addition to this depolarization-stimulated Ca overload-induced SR Ca 2? release as store-overloadinduced Ca release (SOICR). Furthermore, they reported that RyR mutations in catecholaminergic polymorphic ventricular tachycardia (CPVT) reduce the threshold for SOICR by increasing the sensitivity of the channel to activation by luminal Ca 2? and by enhancing the propensity for delayed afterdepolarizations and triggered arrhythmias under conditions of SR Ca 2? overload [13] . CPVT is typically associated with sinus bradycardia [14, 15] . We reported in previous publications that spontaneous SR Ca release is important in the SAN automaticity during b-adrenergic stimulation, and it acts synergistically with activation of membrane ionic currents such as I f to accelerate the sinus rate in intact canine SAN [16] [17] [18] [19] .
Recently, Zhou et al. [20] demonstrated that carvedilol suppressed SOICR independently of its b-blocking effect and prevented CPVT in RyR mutant mice. VK-II-36 is a carvedilol analog that does not significantly block b receptor. We demonstrated that VK-II-36 could suppress ventricular arrhythmias by inhibiting triggered activities [21] . Because SAN activity may share mechanisms underlying both automaticity and triggered activity [22] , we hypothesize that SAN treated with VK-II-36 could reduce spontaneous SR Ca release, leading to suppressed SAN automaticity. In this study, we performed dual optical mapping of transmembrane potential (V m ) and intracellular Ca 2? (Ca i ) with intact canine RAs. We studied the effects of VK-II-36 on the sinus rate at baseline and during badrenergic stimulation to test this hypothesis.
Materials and methods

Langendorff-perfused canine SAN preparation
This study protocol was approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine and the Methodist Research Institute, and conforms to the guidelines of the American Heart Association. We studied isolated canine RAs in 24 mongrel dogs (22-28 kg [23] , we mapped the epicardial side of the tissue. The SAN area was typically located posterior to the sulcus terminalis. Contractility was inhibited by 10-17 lmol/l of blebbistatin [24] , and the motion artifact was negligible even after isoproterenol (ISO) infusion. Pseudo-ECG was recorded with widely spaced bipolar RA electrodes using ISO-DAM8A (World Precision Instruments, Sarasota, FL, USA).
Dual V m and Ca i recordings
Optical mapping analysis was performed as previously described [25] . The hearts were stained with Rhod-2 AM and RH237 (Molecular Probes) and excited with laser light at 532 nm. Fluorescence was collected using two cameras (MiCAM Ultima, BrainVision, Tokyo, Japan) at 1 ms/ frame and 100 9 100 pixels with spatial resolution of 0.35 9 0.35 mm 2 /pixel. After mapping baseline spontaneous beats, pharmacologic intervention was performed in 24 isolated canine RAs. At first, the VK-II-36 dose response (1-30 lmol/l) was evaluated on SAN and surrounding RA (n = 5). Next, we determined the ISO dose response (0.01-1.0 lmol/l) of SAN function under basal conditions (n = 5) and examined the response against ISO during 30 lmol/l VK-II-36 infusion (n = 4). Furthermore, we examined the effects of ryanodine, a RyR inhibitor, on SAN function. In four dogs, the ryanodine dose response (0.1-10 lmol/l) of the sinus rate was evaluated. In the same dogs, we also determined the ISO dose response of the sinus rate during 3 lmol/l ryanodine infusion. To identify effects of caffeine on SAN automaticity, which triggers Ca 2? release by activating RyR, caffeine (20 mmol/l, 2 ml) was given as a bolus injection into the coronary artery within 1 s (n = 3). In three dogs, we examined whether or not the pretreatment of VK-II-36 (30 lmol/l) influences against the effects of caffeine on SAN automaticity. The synthesis of VK-II-36 was described in our previous article [21] .
Data analysis
The sinus rate was defined as the rate generated by SAN activations confirmed with optical mapping. The Ca i and V m traces were normalized to their respective peak-to-peak amplitude for comparison of timing and morphology. The slopes of late diastolic intracellular Ca elevation (LDCAE) were measured from the onsets of LDCAE and to peak levels of LDCAE. The onsets of LDCAE were defined by the time of the transition between negative to positive values in dCa i /dt curves [16] . Student's t tests were used to compare means between two groups. One-way analyses of variance followed by Bonferroni-Dunn test were used to compare three or more groups. Data were presented as mean ± SEM. A P value of \0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors read and agreed to the manuscript as written.
Results
Effect of a SOICR blocker, VK-II-36, on SAN function
The averaged basal sinus rate of intact canine SAN used in the present study was 101 ± 4 bpm (range 82-132 bpm, n = 24). Figure 1 shows changes in the sinus rate after the treatment of VK-II-36 or ryanodine. Both VK-II-36 and ryanodine significantly and dose-dependently decreased the sinus rate. Figure 2 shows the change of activation pattern in SAN and the surrounding RA by VK-II-36. Figure 2b represents an example of the activation pattern on SAN and surrounding RA during spontaneous sinus rhythm. Under basal conditions, the pacemaking sites were located in the middle SAN. The upstrokes of Ca i and V m were nearly simultaneous. Small amplitude LDCAEs in the pacemaking site were observed in the middle SAN at baseline recording in all preparations (arrows in Fig. 2b , range 0.82-2.49 AU/s, n = 24). The treatment of VK-II-36, which blocks SOICR, (Fig. 2c, n = 5) . VK-II-36 infusion caused LDCAE disappearance in the pacemaking site (dotted line arrow in Fig. 2c ). Figure 2d shows that VK-II-36 reduced LDCAE dose-dependently (P \ 0.01).
Effects of VK-II-36 on SAN function in the presence of b-adrenergic stimulation ISO infusion significantly increased the sinus rate, while the pretreatment of VK-II-36 or ryanodine reduced this ISO effect (Fig. 3a) . The ISO (1.0 lmol/l)-induced increase in heart rate was significantly suppressed by VK-II-36 (30 lmol/l, P = 0.02) or ryanodine (3 lmol/l, P = 0.007) (Fig. 3b) . Figure 4 shows the effect of VK-II-36 on the ISO-induced activation pattern change. ISO infusion resulted in an upward (cranial) shift of the pacemaking site (Fig. 4a) , coincident with the appearance of robust LDCAEs (arrows in Fig. 4a ). Figure 4b shows the impact of badrenergic stimulation on the SAN function after 30 lmol/l VK-II-36 treatment. VK-II-36 treatment inhibited ISOinduced upward shifting of the pacemaking site and the augmentation of LDCAE (Fig. 4b) . Figure 4c shows the distance of upward shifting of the pacemaking site dosedependently when ISO infusion was increased from 0.01 to 1.0 lmol/l. VK-II-36 pretreatment almost completely inhibited ISO-induced upward shifting of the leading pacemaker site (ISO 1.0 lmol/l: 5.9 ± 0.3 (VK-, n = 5) vs. 0.8 ± 0.1 mm (VK?, n = 4), P \ 0.01, Fig. 4c ). ISO also dose-dependently augmented LDCAE. When ISO infusion was 1.0 lmol/l, the slope of LDCAE increased to 4.5 ± 0.3 AU/s. VK-II-36 treatment significantly inhibited ISO-induced augmentation of LDCAE (1.0 ± 0.2 AU/s, P \ 0.01, Fig. 4d ).
Effects of VK-II-36 on caffeine-induced changes in sinus node automaticity Caffeine sensitizes RyRs to activation, resulting in increased SR Ca 2? release. We examined whether or not the treatment of VK-II-36 (30 lmol/l) suppresses the effects of caffeine on SAN automaticity (Fig. 5) . When a 2-ml caffeine bolus (20 mmol/l) was injected directly into the right coronary artery, the pacemaking site was soon shifted to upward, and the sinus rate increased from 95.0 ± 8.5 to 158.0 ± 5.0 bpm (P = 0.001). Caffeine enhanced the slope of LDCAE in the pacemaking site from 1.2 ± 0.1 to 4.8 ± 0.3 AU/s (P \ 0.001). The treatment of VK-II-36 (30 lmol/l) did not inhibit the caffeine-induced shifting of the pacemaking site, sinus rate increase (152.7 ± 7.7 vs. 158.0 ± 5.0 bpm, P = 0.59, Fig. 5c ), or LDCAE augmentation (4.2 ± 0.3 vs. 4.8 ± 0.3 AU/s, P = 0.21, Fig. 5d ).
Discussion
The main findings of the present study are as follows. (1) A carvedilol analog, VK-II-36, a SOICR inhibitor, dosedependently decreased sinus the rate like with ryanodine treatment, and it reduced LDCAE in the pacemaking site. release (SOICR) for the pacemaker function in the intact canine SAN, especially during b-adrenergic stimulation. This is the first report demonstrating that SOICR is involved in the increase of the sinus rate, the shift of the pacemaking site in SAN, and the augmentation of LDCAE at the pacemaking site during b-adrenergic stimulation. It has still been discussed whether the Ca 2? clock or membrane clock plays a dominant role in SAN automaticity. Vinogradova et al. [4] reported that the positive chronotropic effect of b-adrenergic stimulation is the result of the [26] reported that SR Ca 2? release does not play a dominant role in pacemaker function in SAN, because ryanodine, which disables the SR Ca 2? release channel, did not abolish spontaneous activity in SAN. Our laboratory reported that ryanodine prevented ISO-induced LDCAE and blunted sinus rate acceleration, and that I f blockade with ZD 7288 modestly blunted but did not prevent LDCAE or sinus rate acceleration by ISO in the intact canine dog [16] . Furthermore, the present study demonstrates that spontaneous SR Ca 2? release inhibition via SOICR blockade by VK-II-36 prevented an ISO-induced upward shift of the pacemaking site in SAN and augmentation of LDCAE, and blunted sinus rate acceleration, which is similar to the effect of ryanodine. Our results suggest that the sinus rate may be partly controlled by the Ca 2? clock via SOICR during b-adrenergic stimulation. We demonstrated that SR Ca 2? release inhibition by ryanodine suppressed the sinus rate both under basal conditions and during b-adrenergic stimulation. SOICR inhibition by VK-II-36 also significantly decreased the sinus rate with LDCAE reduction, which indicates inhibition of spontaneous SR Ca 2? release. These results suggest that SOICR is an important factor for SAN automaticity, especially during b-adrenergic stimulation.
VK-II-36 treatment shifted the pacemaking site downward both under baseline conditions and during b-adrenergic stimulation. This suggests that VK-II-36 is more effective in the superior SAN than the inferior SAN. The mechanism may be explained by the heterogeneity of SAN [27] . The key protein regulator of Ca uptake is phospholamban (PLB), which inhibits SERCA2a in its dephosphorylated state. b-Adrenergic stimulation phosphorylates PLB, relieving its inhibition of SERCA2a and increasing Ca 2? uptake. As a result, spontaneous SR Ca 2? release occurs as a result of activation of the RyR channel by SR luminal Ca 2? . We previously reported that the SERCA2a/ PLB molar ratio at SAN sites was significantly lower than at RA sites, and was not significant but tended to be lower in the superior SAN than in the inferior SAN in canine hearts [16] . These may be involved in the heterogeneous effect on SAN function by SOICR inhibition. exchanger, leading to an increasein the sinus rate. VK-II-36 inhibits SOICR. However, the detailed mechanism of the VK-II-36-induced effect has yet to be determined. Jiang et al. [12] reported that CPVT RyR mutations enhance SOICR by increasing the channel sensitivity to activation by luminal Ca 2? , and alterations in RyR function are likely to contribute to the reduced threshold for SOICR, resulting in the high incidence of DAD-associated ventricular tachycardia. Our results could suggest that VK-II-36 inhibits spontaneous SR Ca 2? release by increasing the threshold for luminal Ca 2? activation of RyR. VK-II-36 inhibited ISO-induced effects in canine intact SAN, but did not inhibit caffeine-induced effects. Kong et al. [28] reported that caffeine triggers Ca 2? release by reducing the threshold for luminal Ca 2? activation of RyR. The present results suggest that caffeine reduced the threshold for luminal Ca 2? activation elevated by VK-II-36 and might cancel out the VK-II-36-induced inhibitory effect on SR Ca 2? release. As a result of that, caffeine shifted the leading pacemaker site upward in SAN and augmented LDCAE at the pacemaking site, and it increased the sinus rate despite VK-II-36 treatment.
Another carvedilol analog, VK-II-86, is known to have no effects on heart rate in either wild-type or R4496C-heterozygous mice [20] . In comparison, VK-II-36 significantly reduced the sinus rate in canine hearts. The mechanisms by which VK-II-36 exhibits different effects on mice and canine SA nodes are unclear. One possibility is that the mice sinus node, which operates at an intrinsic rate many times faster than that of the canine sinus node, does not depend on the calcium release from the RyR for heart rate control. However, such a view is not congruent with experimental results showing that calcium homeostasis in mouse SA nodes also plays an active role in heart rate acceleration [29] . Alternatively, the RyR in the mice sinus nodes may be less sensitive to the VK compound than the RyRs in canine sinus nodes. Further studies are required to test these hypotheses.
Limitations
There are several limitations in the present study. First, we did not directly measure the SR Ca 2? release. It is therefore possible that some components of LDCAE might have originated from the membrane Ca 2? currents. However, we think LDCAE originated from the SR Ca 2? release, because LDCAE was suppressed by VK-II-36, which reduced SR function via the SOICR blocking effect. Second, the VK-II-36 agent is a carvedilol analog that blocks SOICR but does not block b receptor. However, the other effects cannot be excluded. Yokoyama et al. [30] reported carvedilol inhibits the Ca current, delayed rectifier K ? current, and hyperpolarization-activated inward current in SAN cells with voltage clamp experiments. VK-II-36 may have the same effects and cause a suppression of spontaneous pacemaker activity by the inhibition of various currents. Third, the blebbistatin used for inhibiting cardiac contractility is an excitation-contraction uncoupling drug and may influence the intracellular Ca dynamics. Fedorov et al. [24] reported that blebbistatin increased resting fluorescence by 39 %. We cannot rule out the possibility that blebbistatin may influence our data and the interpretation of the results. Fourth, we reported that LDCAEs were observed in only 4 of 25 preparations in the previous article [16] . The exact reason why the appearance of LDCAE in this study is different from that in the previous article is unclear. It might be attributed to improved experimental techniques and data quality, allowing better detection of small LDCAEs in this study.
Conclusions
In conclusion, SOICR is important for SAN automaticity. The sinus rate might be partly controlled by the Ca 2? clock via SOICR during b-adrenergic stimulation. Spatial heterogeneity of SOICR may be a key in determining the site of the dominant pacemaker. Further studies on SOICR may lead to the development of novel treatments for SAN dysfunction.
